Connect with us

Business

Tech startup Hyphen is bringing AI to the lunch line — with help from Cava and Chipotle

Published

on

Tech startup Hyphen is bringing AI to the lunch line — with help from Cava and Chipotle


At a challenging time for the restaurant industry, major chains like Chipotle and Cava are putting money behind automated makelines from startup Hyphen.

The San Jose, California-based company aims to help restaurants achieve two key goals in a hyper-competitive environment: speedy throughput and good customer service. The technology makes for a less chaotic and more “elegant experience” for workers and guests alike, co-founder and CEO Stephen Klein told CNBC in an interview.

“We’re probably making a bowl every 10 to 15 seconds. At peak throughput, we have more capacity usually than they do demand, especially … for lunch and dinner rushes,” Klein said.

That efficiency has brought increased interest across the industry. In August 2025, Hyphen closed a Series B round of financing that included up to $10 million from Cava. Chipotle said it has invested a total of $25 million into Hyphen via its Cultivate Next venture fund through the third quarter of 2025.

The $25 million Series B round will help Hyphen scale its production and rollout across restaurants in the U.S. Its production will ramp with Re:Build Manufacturing, a company based in Kalamazoo, Michigan. Chipotle’s Hyphen makeline is in San Jose for modification after an in-restaurant test. Cava will test and pilot its tech for a second makeline to serve digital and takeout orders in the back of its kitchen in the future.

A finished burrito bowl assembled by Chipotle and Hyphen’s automation technology.

Source: Chipotle Mexican Grill

Hyphen’s technology solves for both a speed and labor issue, helping to automate part of the service process that can be repetitive and challenging to fill.

“You can have, somebody is selling ingredients on top, while the rest of this stuff is happening underneath,” he said of the makeline, which relies on a series of robotic hands to prep salads and bowls under a long table, out of public view, sending them down the row.

The makelines cost between $50,000 and $100,000 to purchase, and restaurant customers are often getting a return on investment in under a year, Klein said. They operate 95% of the time, but during the rare moments they’re down, workers can jump in to complete orders, the way an escalator would turn into stairs, he said.

Another key feature is cutting down on food waste. The technology tracks ingredients “down to the gram,” Klein said.

“We’re perfectly portioning every ingredient, we’re able to help them save on food costs, or at least reduce food costs in some way,” he said.

The idea of the company began when Klein and his co-founder Daniel Fukuba built a fully robotic food truck, which launched in Los Angeles three months before the pandemic started. They changed gears to launch Hyphen soon after that.

“When the pandemic happened, we kind of just had to share that into another direction. We had luckily been talking to other restaurant partners about licensing our technology for them, and we decided … it just made a lot more sense to help restaurants that are already around today,” Klein said.

Technology innovation will likely continue to be a key trend in the restaurant sector after a brutal year for many of the industry’s leaders. Shares of Cava and Chipotle are down nearly 50% and 40% year-to-date, respectively, after pullbacks from key demographics including younger consumers. Sweetgreen, another competitor in the healthy salad and bowl space, is down nearly 80% on the year.

Sweetgreen sold its robotics unit, Spyce, to mealtime platform Wonder earlier this year for $186.4 million. Sweetgreen had acquired Spyce to build its automated Infinite Kitchens, and it will continue to use the technology.

Klein said Hyphen is talking to major brands and food service providers for college campuses and office parks as it looks to not only evolve the makeline, but also provide data that comes from the food prep and distribution. The company aims to develop more software in the future, including tools for food prep scheduling to be used in the back of the house.

One area that’s not on the menu, at least for now, is the fast food sector.

“We’re really trying to help people that have really a high mix or high customization in terms of what their guests are ordering, as well as high volume. So that’s kind of our strike zone,” he said.

Wonder CEO Marc Lore on Spyce acquisition, robotic kitchen technology and growth outlook



Source link

Business

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Published

on

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals


Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments. 

In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall behind on those early drug trials. 

These include hospital contracting as well as ethical reviews and approvals, both of which he called “clunky processes that take too long and are leaving us noncompetitive with the countries that are moving a lot faster.” He also pointed to the process for submitting and receiving approvals for Investigational New Drug, or IND, applications, which companies submit to test a product in humans. 

“We walked into a mess,” Makary said, referring to how behind China the U.S. was in terms of Phase 1 clinical trials conducted in 2024. 

Food and Drug Administration Commissioner Marty Makary speaks in the Oval Office at the White House on Jan. 29, 2026.

Samuel Corum | Getty Images

He said the FDA is “looking at everything,” such as whether it can partner with health systems and academic medical centers on the pre-IND process. That refers to when companies consult the FDA before formally filing an application. 

Makary said the Trump administration should “partner with industry to help them deliver more cures and meaningful treatments for the American public because that is a common bipartisan goal that we all want. And we’re going to get it done in this administration.”

China’s biotech ecosystem has flourished over the last several years, driven by massive state investment, a vast talent pool and accelerated regulatory reforms. Once known for being a low-cost manufacturing base that pumps out copycats, China is rapidly evolving into a global innovation powerhouse. 

Data from Global Data and Morgan Stanley shows that China now conducts more clinical trials than the U.S., accounts for nearly a third of new global drug approvals and is on pace to reach 35% of FDA approvals by 2040. 

U.S. policymakers have been under pressure to take steps to boost innovation domestically. 



Source link

Continue Reading

Business

Mark Zuckerberg arrives to testify in social media addiction trial

Published

on

Mark Zuckerberg arrives to testify in social media addiction trial


In one such case, 29 state attorney generals are pushing a California federal court to demand that the platforms make a number of changes immediately, before any trial, including forcing Meta to remove all accounts known to belong to users under 13 years of age.



Source link

Continue Reading

Business

India eyes diversification of crude oil sources; Piyush Goyal says would ‘love’ high-quality coking coal from US – The Times of India

Published

on

India eyes diversification of crude oil sources; Piyush Goyal says would ‘love’ high-quality coking coal from US – The Times of India


Goyal said India can produce goods in areas where US manufacturers may not be competitive.

India is looking to diversify its sources of crude oil, Commerce Minister Piyush Goyal has said. Goyal’s comments assume significance in light of the India-US trade deal joint statement which lowers tariffs on Indian exports to 18%. The Donald Trump administration has also removed the 25% penal tariffs on India on the condition that it stops buying crude oil from Russia.India’s crude imports from Russia have dropped since the US imposed sanctions on two major Russian oil firms in late 2025. According to reports, the share of Russian crude in India’s oil imports has dropped to the lowest level since late 2022 and analysts expect the numbers to drop further in the coming months.

India to Add $26 Trillion to Economy, Negotiating FTAs from Strength: Piyush Goyal

India would ‘love’ high-quality coking coal from US

Piyush Goyal said India is looking to broaden its sourcing of crude oil and coking coal and would welcome supplies of premium-quality coking coal from the United States.Also Read | 18% tariffs, boost to exports, agriculture protected: How India benefits from trade deal with US? Explained“We want to diversify our oil sources. I want to diversify the source of coking coal for example. I am dependent on 2 or 3 geographies (for that) and prices keep fluctuating. I would love to have American coking coal which is high quality coming to India,” he said according to a PTI report.He noted that the US is well positioned to supply several products that are critical for India’s economic growth, including graphics processing units used in artificial intelligence, infrastructure and equipment for data centres, and high-performance computing systems.Goyal said India can produce goods in areas where US manufacturers may not be competitive, while America can serve as an important provider of technology and investment capital.Also Read | Trump removes 25% penal tariff: What happens if India stops buying Russian crude oil?He added that demand for aircraft from the US is already estimated at about $100 billion over the next five years, with additional capacity required to expand domestic aviation and help lower fares.Under the proposed interim trade pact with the United States, India has conveyed its intent to procure goods worth $500 billion from America over the next five years. An Indian delegation is scheduled to travel to the US next week to conclude the legal drafting of the agreement, which is expected to be signed in March.Piyush Goyal said entering into a trade agreement with the US would be beneficial for India, noting that it would create significant opportunities for domestic businesses, particularly in labour-intensive sectors and technology-driven services.Referring to India’s free trade agreements, Goyal noted that nine such pacts have been concluded over the past four years. He added that these deals were negotiated from a position of confidence, emphasising that India now engages in trade talks assertively, without defensiveness, and with a focus on long-term interests.



Source link

Continue Reading

Trending